Whenever I read natural history studies, I think that they should come with the disclaimer that they are investigating a particular question in a particular setting and that all such studies rest on assumptions that the investigators make.
Maybe the most noticeable conclusion from natural history research is that there is a very wide spectrum ranging from the mildest to the most severe outcomes. Over the last decades, our understanding of this wide spectrum has increased, which unfortunately only made it harder to define what multiple sclerosis (MS) is and where the disease begins. This spectrum now ranges from the radiologically isolated syndrome 1 to the different subtypes of established MS. 2 Epidemiological research is also not made easier by the fact that the diagnostic criteria for MS have changed multiple times from the Poser et al. 3 criteria, which included no clear definition of primary progressive multiple sclerosis (PPMS) and required two clinical relapses for a diagnosis of relapsing-remitting multiple sclerosis (RRMS), to the most recent MacDonald criteria which rely heavily on imaging findings for all subtypes of MS, 4 a technique that was unavailable when the major natural history cohorts were established.
Given this background, I believe that epidemiological studies can be useful to address a particular question in a particular setting. Also given this background, I fail to see the two opinions presented here as very controversial. Zhang and Tremlett's approach is about the risk and timing of developing secondary progression in a -hopefully large and representative -cohort of patients with RRMS, and the findings from such research can be helpful for counselling patients in the early stages of the disease. The underlying assumption here is that RRMS is driven by the same factors across the cohort, so that it is fair to say that all patients are 'at risk' of developing progression given enough time.
I see Vukusic's approach as an attempt to highlight and focus on the features of progressive MS, in particular on the differences and similarities of PPMS and secondary progressive multiple sclerosis (SPMS). Such studies are not necessarily useful for counselling patients at the onset of RRMS, but can help to understand the phenomenon of progression better. The assumption here may be that progression is a possible outcome that not all RRMS patients are at risk for, but which affects only a subgroup of the whole population.
In the absence of clarity on whether either of these underlying assumptions is the only correct one, I believe that both approaches are valid and that both can increase our understanding of progression in MS.
However, it may be even more important to realize that epidemiological research -whichever way it is conducted -has its limits and will not give us a full understanding of progression. To get closer to understanding progression, and ultimately to be able to treat it, we will need a concerted effort that brings together research into the pathology, genetics, biochemistry, biomarkers, imaging findings and clinical outcome measures of progression in MS. I am hopeful that initiatives like the International Progressive MS alliance, and programmes by national MS societies directed at progressive MS, will bring us closer to these goals.
M Koch

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.
